Skip to content

Effect of Longmu Gegen Decoction on herpes zoster and its effect on T cell subsets

Traditional Chinese medicine

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2100005123
Enrollment
Unknown
Registered
2021-08-02
Start date
2021-08-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster

Interventions

Sponsors

Xiyuan Hospital of CACMS
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Meets the typical diagnostic criteria for herpes zoster; 1-3 days from onset to treatment; Pain VAS score less than 6 points; Between the ages of 18 and 80; Untreated; No cognitive impairment; Volunteer to be tested and sign an informed consent form.

Exclusion criteria

Exclusion criteria: Herpes zoster special type, such as meningeal herpes zoster, visceral herpes zoster, herpes zoster without rash, generalized herpes zoster; Allergic to Chinese medicine or unwilling to Chinese medicine treatment; Patients with severe heart, lung and other systemic diseases and malignant tumors; Patients with systemic lupus erythematosus and other immune diseases and the application of immunosuppressive agents; Pregnant or lactating women and those with a history of mental illness; Severe adverse reactions occurred during the period of taking the drug and known allergies to the drug; Join other clinical investigators.

Design outcomes

Primary

MeasureTime frame
T cell subsets (CD3+, CD3+CD4+, CD3+CD8+);

Countries

China

Contacts

Public ContactZhongxue Fu
fzxpersonal@aliyun.com13811982053

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026